ArticleCureus2025
Effect of Low-Dose Atropine on Choroidal Thickness in Children With Myopia Progression.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy of 0.01% low-dose atropine therapy for the myopia and premyopia in children: a meta-analysis and systematic review.BMC ophthalmology · 2026Pooled it
- Low-Concentration Atropine for Myopia Management: Recent Evidence and Clinical Implications.Ophthalmology and therapy · 2026Review
- Choroidal Structural and Vascular Changes During Myopia Progression and in Response to Myopia Control Interventions: A Systematic Review.Clinical ophthalmology (Auckland, N.Z.) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe present study aims to evaluate the effect of low-dose atropine (0.01%) on choroidal thickness in children with progressive myopia. A secondary objective was to compare the rate of myopia progression between children treated with low-dose atropine (0.01%) and those receiving placebo eye drops (preservative-free carboxymethyl cellulose 0.5%) through changes in equivalent, axial length (AXL), and best-corrected visual acuity (BCVA). STUDY
designA prospective case-control interventional study was conducted in the department of ophthalmology at a tertiary eye care center in eastern India. MATERIALS AND
methodsA total of 87 children aged 5-16 years with bilateral progressive myopia were recruited and randomly assigned into two groups. Spherical equivalence, AXL, and choroidal thickness (sub-foveal and at 1500 and 3000 microns nasal and temporal to the fovea) were documented at baseline,1 month,3 months, and 6 months.44 children in group A received treatment with once-daily dosing of atropine at bedtime, while 43 children in group B received a placebo eyedrop.
resultsChildren in group A showed a significant increase in overall choroidal thickness at 3 and 6 months (11+/-9.67) and (18+/-13.43) microns, respectively, which showed a significant correlation with the progression of myopia (in terms of spherical equivalence and AXL).
conclusionLow-dose atropine induced a significant choroidal thickening effect, which was associated with slower progression of myopia in the treatment group.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.